A Blockbuster Drug and Its Hidden Price War

The International Consortium of Investigative Journalists (ICIJ) published a major investigative series titled 'Cancer Calculus' on April 13, 2026, exposing alleged layers of misconduct surrounding Merck's cancer drug Keytruda. According to the reporting, Merck has systematically used patent strategies and pricing policies to restrict global access to the drug while building it into a blockbuster product.

Why Keytruda Matters

Keytruda is currently the world's best-selling cancer drug. As a PD-1 inhibitor immunotherapy, it is used across multiple cancer types including lung, skin, and stomach cancer, and serves as Merck's primary revenue driver. According to multiple international reports, the annual treatment cost in the United States runs into hundreds of thousands of dollars, making it effectively inaccessible for uninsured patients.

ICIJ's reporting goes beyond drug pricing, focusing on Merck's patent strategy. Even as original patents expire, the company allegedly employs so-called 'evergreening' techniques — reformulations, new indications, and combination therapies — to artificially extend its monopoly. Industry sources suggest Keytruda is protected by dozens of patents, potentially delaying biosimilar entry by years.

Counterfeits and Insurance Denials: A Double Barrier

The investigation also flagged two additional issues. First, counterfeit Keytruda is reportedly spreading in some countries as a consequence of prohibitive pricing, posing direct threats to patient safety.

Second, insurance companies in markets like the United States are increasingly denying or delaying Keytruda prescriptions. One patient quoted in the coverage described being denied 'the medication that is keeping you alive.' Analysts see this as a structural collision between drug pricing and private insurance architecture.

Within the Tradition of Investigative Journalism

ICIJ, known for the Panama Papers (2016) and Pandora Papers (2021), is a nonprofit independent news organization funded entirely by donors. Cancer Calculus marks a significant expansion from financial corruption into the pharmaceutical and healthcare sector.

Drug pricing opacity and patent system abuse are central issues in global health equity debates, directly linked to WHO and government discussions on medicine access.

Outlook [Expert Analysis]

The ICIJ report is likely to accelerate international regulatory debates on pharmaceutical patent practices. Legislative momentum around drug pricing transparency and evergreening restrictions is already building in the U.S. Congress and the European Union.

Some Keytruda patents are set to expire around 2028–2030, and whether biosimilars can successfully enter the market will likely reshape the global oncology drug landscape. However, if Merck pursues additional patents and clinical data strategies to maintain dominance, meaningful price reductions may remain years away.

Whether investigative reporting translates into policy change ultimately depends on political will and industry response.